Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-025-03044-y, published online 12 May 2025
Following publication of the article, the authors noticed two small errors introduced during the typesetting process of the article. Firstly, figures were inadvertently published in black/white, rather than in colour. Secondly, a label within Figure 3 was adjusted in error during the typesetting process; the upper-scale label in Figure 3a, for EBV DNA, should have read “≥4000 copies/mL”, not “4000 copies/mL”. The figure has been corrected.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Lan, K., Li, S., Jia, G. et al. Correction: Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma. Br J Cancer 133, 912 (2025). https://doi.org/10.1038/s41416-025-03077-3
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41416-025-03077-3
